June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Effects of Pentosan Polysulfate Sodium on Retinal Cells Viability and RPE Regeneration In Vitro
Author Affiliations & Notes
  • Dimitrios Ntentakis
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Victor Correa
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Toshio Narimatsu
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Peter Glavas
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Demetrios Vavvas
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Nikolaos Efstathiou
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Dimitrios Ntentakis None; Victor Correa None; Toshio Narimatsu None; Peter Glavas None; Demetrios Vavvas Sumitomo/Sunovion, Cambridge Polymer Group, TwentyTwenty, Code C (Consultant/Contractor), Scientific Advisory Board Olix Pharma, Medical Advisory Board Valitor , Code E (Employment), Co-founder Drusolv Therapeutics, Code O (Owner), Inventor in Patents held by Massachusetts Eye and Ear, Code P (Patent); Nikolaos Efstathiou None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2996. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dimitrios Ntentakis, Victor Correa, Toshio Narimatsu, Peter Glavas, Demetrios Vavvas, Nikolaos Efstathiou; Effects of Pentosan Polysulfate Sodium on Retinal Cells Viability and RPE Regeneration In Vitro. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2996.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : PPS is a low molecular weight heparin-like molecule used in the treatment of interstitial cystitis. Recently, long-term use of PPS has been associated with a bilateral progressive maculopathy, characterized by hyper-pigmented lesions, subretinal deposits and speckled parafoveal RPE atrophy and can even progress after PPS discontinuation. There is growing clinical evidence supporting the association between PPS use and maculopathy development, but no pathophysiological mechanism has been described yet. In this setting, we investigated PPS toxicity on cell lines representing the outer retina / choroid complex. We also explored the effects of PPS on RPE proliferation and migration, as well as its potential interference with a heparin-binding EGF-like growth factor (HB-EGF) signaling.

Methods : Retinal pigment epithelial cell line (ARPE-19), photoreceptor cell line (661W), primary human retinal microvascular endothelial cell (HRMEC), and human endothelial cell line (HUVEC) were cultured with PPS for 24h and 72h after confluency, in 96 well plates. Toxicity was assessed with the CCK-8 cell counting kit and the LDH release kit. The effect of PPS on HB-EGF-induced RPE proliferation and migration was assessed by the CCK-8 kit and the scratch-wound assay.

Results : PPS was not toxic to RPE or photoreceptor cells with doses up to 1mg/ml. PPS was toxic to HUVEC at doses greater than or equal to 7.9 µg/ml, and reduced 79% of cell viability at 1mg/ml after 72h. PPS was also toxic to HRMEC at doses greater than or equal to 31.25 µg/ml and reduced 38% of cell viability at 1mg/ml after 72h. PPS at 1mg/ml completely prevented HB-EGF-induced proliferation and migration of ARPE-19 cells.

Conclusions : Our data suggest a pathophysiological mechanism for PPS maculopathy that implicates vascular endothelial cells more than RPE and significantly impaired the HB-EGF-induced wound repair in RPE cells. Chronic exposure to PPS could damage the choroidal vessels and disrupt the wound-healing response of the RPE, potentially predisposing to RPE atrophy. These findings are aligned with the clinical presentation of PPS maculopathy, and recent angiographic findings suggesting that choroidal injury precedes the pigmentary changes in the disease’s natural history.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×